"rationale","uuid:ID","description","instanceType","name","id","label"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","6a5ce33e-a91b-466f-9e51-12fba49338ee","The main design for the study","StudyDesign","Study Design 1","StudyDesign_1",""
